Navigation Links
Protege Encore Clinical Trial Evaluates New Investigational Approach For Individuals Recently Diagnosed With Type 1 Diabetes
Date:5/10/2010

WELLINGTON, Fla., May 10 /PRNewswire-USNewswire/ -- Dr. Richard Hays announced today that he is now recruiting children with newly diagnosed type 1 diabetes for Protege Encore, a randomized, placebo-controlled Phase III clinical trial. This is the second of two Phase III studies testing the safety and efficacy of an investigational drug called teplizumab. The first study, known as Protege, has completed enrollment of more than 530 subjects with type 1 diabetes. There is currently no approved therapy to slow the progression of type 1 diabetes.

In patients with type 1 diabetes, T cells of the immune system attack and destroy beta cells that are located in the pancreas and make insulin. Teplizumab works by binding to CD3 receptors on the surface of the T cells and, by doing so, may modulate the autoimmune attack on pancreatic beta cells and preserve or protect these cells. If effective, patients may require less injected insulin and their blood glucose levels may be easier to control.

In an earlier trial of teplizumab, a small group of subjects with diabetes of recent onset were noted to have improved function of their beta cells, improved glucose control, and reduced insulin requirements for up to two years. These findings are being further studied in the Protege and Protege Encore clinical trials.

The Protege Encore trial is designed to determine if teplizumab can preserve pancreatic insulin production, which may make diabetes easier to manage. "We have a lot of enthusiasm about the teplizumab studies and their implications. It is hoped that one day we can offer a new treatment option to help patients better manage their disease," Dr. Hays commented.

Approximately 125 study sites across 16 countries will be enrolling 400 individuals who have been to a physician with signs and symptoms of type 1 diabetes within the past 12 weeks. Most study sites are enrolling individuals 8–35 years old, and Dr. Hays is enrolling individuals 8–17 years old. Subjects will receive one of three study treatment regimens, or placebo. Subjects will be followed over a 2-year period.

Additional information on Protege Encore and all participating study sites is available at www.protegediabetes.org/news.  Dr. Hays can also be reached directly at 561-641-7736.

About Dr. Richard Hays

Richard M. Hays, M.D., P.A., completed his undergraduate education at Johns Hopkins University in Baltimore, his M.D., at the University of Florida College of Medicine in Gainesville, and his residency at the Duke-Watts Family Medicine Residency Program in Durham, N.C. He is board certified in family medicine and is a fellow of the American Academy of Family Physicians (AAFP). Dr Hays has been in private practice since 1989, with staff privileges at Wellington Regional Medical Center in Florida, where he is chief of the Department of Family Practice. Dr. Hays is a member of several professional societies, including AAFP and the Florida Academy of Family Physicians. He is also certified by the National Committee on Quality Assurance for special qualification in care of patients with diabetes.


'/>"/>
SOURCE Richard M. Hays, M.D., P.A.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes
2. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
3. Novocell Becomes ViaCyte, Inc., as it Accelerates Pre-Clinical Development of a Stem Cell Derived Treatment for Diabetes
4. Stereotaxis Updates Progress on Major Clinical Initiative Related to Electrophysiology (EP) Treatment of Ventricular Tachycardia
5. US HIFU Receives Unanimous Approval to Continue the Clinical Investigation of High Intensity Focused Ultrasound (HIFU) for Treatment of Prostate Cancer
6. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2010 Financial Results
7. Omeros Reports Additional Phase 2 Data Showing Multiple Clinical Benefits In Patients Undergoing Meniscectomy Surgery
8. US Oncology Meets With Leading Pharmaceutical and Biotech Companies to Design Clinical Trials for the Cancer Fighting Drugs of Tomorrow
9. OrbusNeichs Genous(TM) Bio-engineered R stent(TM) Demonstrates Excellent Safety and Clinical Outcomes in High-Risk Elderly Patients
10. Lotus Pharmaceuticals Laevo-Bambuterol Received SFDA Approval to Commence Clinical Trials
11. Novavaxs Seasonal Influenza VLP Vaccine Candidate Shows Positive Results in a Phase II Clinical Trial in Older Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... 6, 2017  Medical professionals are expected ... while treating their patients. Medical simulations offer ... involving patients. Simulation provides a safe method ... out procedures, refine techniques and build confidence, ... new technology, such as augmented reality, will ...
(Date:9/6/2017)... , Sept. 6, 2017 Eli Lilly ... it will present new data for galcanezumab and lasmiditan, ... of the International Headache Society (IHC) taking place Sept. ... Lilly will highlight new, long-term data from an ... doses of galcanezumab (120 mg and 240 mg) for ...
(Date:9/5/2017)... , Sept. 5, 2017  Getinge, a ... created a vibrant charitable donation program -- "Color ... support congenital heart defect research by The Children,s ... and the general public are encouraged to download ... submit the completed artwork to the gallery on ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... 2017 , ... “The Trials I Face to Receive God’s Grace”: a ... aspirations and goals to better one’s life through God. “The Trials I Face to ... all the wrong places, found a love for writing. Green feels that expressing his ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... gathering of executive marketers this week about the value of senior executives, pointed ... that has happened in business has brought us to the present and will ...
(Date:9/20/2017)... ... September 20, 2017 , ... “They Sang At Her Funeral”: a ... murderer starts revealing the skeletons in their closets. “They Sang At Her Funeral” is ... fifty-six years young and married with five children and twelve grandchildren. Before becoming a ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... addition of strategic marketing leader, Denise Flannery, to its strategic advisory and client ... Management Consultant, Denise will work with clients across different industries to develop and ...
(Date:9/19/2017)... , ... September 19, 2017 ... ... that Scott McFarland has joined its executive team as the President of ... innovative value-based care management systems and contact centers. , “Scott is a ...
Breaking Medicine News(10 mins):